Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

sacituzumab govitecan (SG)とPARP阻害剤タラゾパリブの逐次投与戦略が、三重陰性乳がんの治療で有効性を保ちながら毒性を軽減する可能性。逐次投与アプローチは良好に耐容され、PFSの中央値が7.6か月と、同時投与の2.3か月に比べて優れていることが確認　OA https://t.co/EdNqSP7HXW

RT @MGH_RI: Researchers from @MGHCancerCenter and colleagues published Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential T…

Researchers from @MGHCancerCenter and colleagues published Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer, in @AACR_Cancer this past month. Read more: https://t.co/yn

RT @DFCI_BreastOnc: Read this new @CCR_AACR study 👇👇 #AntibodyDrugConjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor…